Compare Neurocrine Biosciences Inc (NBIX) vs Ryanair Holdings plc (RYAAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Ryanair Holdings plc — how do they compare? Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B), while Ryanair Holdings plc trades at $54.24 (market cap $27.11B). The key difference: Ryanair Holdings plc is the larger of the two by market cap, and Ryanair Holdings plc pays a 1.66% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Ryanair Holdings plc for 72 Days on average.
| NBIX | RYAAY | |
|---|---|---|
Market Cap | $14.36B | $27.11B |
Volume | 1,237,180 | 2,427,380 |
Sector | Health | Industrials |
52-Week High | $185.50 | $73.82 |
52-Week Low | $123.10 | $51.95 |
Typical Hold Time | 23 Days | 72 Days |
Enterprise Value | $14.37B | $24.18B |
Dividend Yield | — | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $141.25, down 1.55% on the day, with a bearish technical signal driven by moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and has beaten EPS estimates in recent quarters. Recent news highlights pipeline progress in Prader-Willi syndrome and executive appointments.
The outlook is supported by robust analyst consensus (86.49% buy ratings) and a $204.18 price target, but risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock offers growth potential from expanding rare-disease assets, contingent on successful commercialization.
RYAAY trades at $54.04, down 3.5% on the day, with a bearish technical signal from moving averages. The company reported revenue of $13.95 billion in 2025 and net income of $1.61 billion, with a P/E ratio of 13.43. Recent earnings have been mixed, with a miss in Q2 2026. News highlights include CEO commentary on Boeing MAX 10 delays and concerns over fuel costs impacting future airfares.
The stock presents a valuation opportunity with low P/E and EV/EBITDA multiples, but faces near-term headwinds from volatile fuel prices and reduced traffic forecasts. Analyst consensus is moderately bullish, with 65% buy ratings, though technical indicators suggest caution. Key risks include oil price sensitivity and competitive pressures in the European airline sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →
